Next Article in Journal
Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients
Previous Article in Journal
Dyslipidemia in Renal Transplant Recipients
Previous Article in Special Issue
COVID-19: Impact on Lung Transplant Activity at a Large Brazilian Hospital
Article

SARS-CoV-2 Infection of Unvaccinated Liver- and Kidney-Transplant Recipients: A Single-Center Experience of 103 Consecutive Cases

1
College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
2
Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
3
Division of Solid Organ Transplantation, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR 72205, USA
4
Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
5
Division of Nephrology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Macé M. Schuurmans
Transplantology 2022, 3(2), 200-207; https://doi.org/10.3390/transplantology3020021
Received: 13 April 2022 / Revised: 31 May 2022 / Accepted: 10 June 2022 / Published: 16 June 2022
(This article belongs to the Special Issue Solid Organ Transplantation in the Era of COVID-19)
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was declared a pandemic in March 2020. Its reported impact on solid-organ-transplant-recipient morbidity and mortality has varied. The aim of this study was to present the effect of transplant status, patient comorbidities and immunosuppression modality on the survival of solid-organ-transplant recipients who contracted SAR-CoV-2 during the pre-vaccination era, at a single academic transplant center. Patients (n = 103) were assessed for 90-day mortality. A univariate analysis identified an age of over 60 years (HR = 10, p = 0.0034), Belatacept (HR = 6.1, p = 0.022), and Cyclosporine (HR = 6.1, p = 0.0089) as significant mortality risk factors; Tacrolimus was protective (HR = 0.23, p = 0.022). Common metabolic comorbidities (hypertension, diabetes, obesity) did not stand out as risk factors in our patient cohort. This study on the unvaccinated is expected to facilitate a paired comparison of outcomes in transplanted patients who contracted SARS-CoV-2 during the latter period of the pandemic, when broad SARS-CoV-2 vaccination and novel antibody treatments became broadly available. View Full-Text
Keywords: solid-organ transplant; COVID-19; unvaccinated; immunosuppression solid-organ transplant; COVID-19; unvaccinated; immunosuppression
Show Figures

Figure 1

MDPI and ACS Style

Hardgrave, H.; Wells, A.; Nigh, J.; Osborn, T.; Klutts, G.; Krinock, D.; Rude, M.K.; Bhusal, S.; Burdine, L.; Giorgakis, E. SARS-CoV-2 Infection of Unvaccinated Liver- and Kidney-Transplant Recipients: A Single-Center Experience of 103 Consecutive Cases. Transplantology 2022, 3, 200-207. https://doi.org/10.3390/transplantology3020021

AMA Style

Hardgrave H, Wells A, Nigh J, Osborn T, Klutts G, Krinock D, Rude MK, Bhusal S, Burdine L, Giorgakis E. SARS-CoV-2 Infection of Unvaccinated Liver- and Kidney-Transplant Recipients: A Single-Center Experience of 103 Consecutive Cases. Transplantology. 2022; 3(2):200-207. https://doi.org/10.3390/transplantology3020021

Chicago/Turabian Style

Hardgrave, Hailey, Allison Wells, Joseph Nigh, Tamara Osborn, Garrett Klutts, Derek Krinock, Mary K. Rude, Sushma Bhusal, Lyle Burdine, and Emmanouil Giorgakis. 2022. "SARS-CoV-2 Infection of Unvaccinated Liver- and Kidney-Transplant Recipients: A Single-Center Experience of 103 Consecutive Cases" Transplantology 3, no. 2: 200-207. https://doi.org/10.3390/transplantology3020021

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop